在COVID期间推迟细胞削减手术的患者的瘤结果 时间
Debabrata Barmon1, Eshwarya Jessy Kaur2, Upasana Baruah1
1Department of Gynaecological Oncology, Dr B Borooah Cancer Institute, Tata Memorial Hospital, Guwahati, India.
Indian journal of surgical oncology
|March 21, 2025
概括
在先进的上皮卵巢癌 (EOC) 中,经过4次以上的新辅助化疗 (NACT) 后的延迟细胞减少手术与较差的生存结果有关. 这表明标准的NACT循环通常足以获得最佳的患者益处.
科学领域:
- 妇科瘤学 妇科瘤学
- 医学瘤学 医学瘤学
- 手术瘤学手术瘤学
背景情况:
- 对于先进的上皮卵巢癌 (EOC),标准的新辅助化疗 (NACT) 涉及3-4个周期,但最佳持续时间仍在争论中.
- 由于COVID-19大流行导致手术推迟,因此需要对EOC的延迟细胞还原手术 (CRS) 进行评估.
研究的目的:
- 评估癌症结局,特别是无进展生存率 (PFS) 和总生存率 (OS),在经过延迟CRS的高级EOC患者中.
- 为了确定影响OS和PFS的预后因素,延迟CRS患者.
主要方法:
- 在第三级癌症研究所进行了回顾性观察性研究.
- 延迟CRS组 (经过5个NACT周期) 和对照组 (经过3-4个NACT周期) 之间的结果比较.
- 评估完整的细胞减少率,化疗反应,CA 125水平,PFS和OS.
主要成果:
- 延迟的CRS与完全细胞减少率 (50%vs71%) 和完全化疗响应率 (24.13%vs28.15%) 的显著降低有关.
- 与对照组相比,接受延迟CRS的患者的PFS (7个月 vs 16个月) 和OS (34个月 vs 55个月) 显著较短.
- 在58%的延迟CRS病例中,COVID-19是延迟的原因.
结论:
- 超过3-4个循环的化疗可能会降低晚期EOC患者的生存率.
- 延迟的CRS,通常是由于COVID-19流行病等因素造成的,与较差的瘤结果有关.
- 这种方法可能为在初始NACT循环后被认为无法操作的选定患者提供生存益处.
更多相关视频
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
5.5K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
196
相关概念视频
01:21Cancer Survival Analysis
315
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
315
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K